S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Navigating the Rebound in FDA Accelerated Approvals

Accelerated approvals accounted for nearly one-quarter of novel drug authorizations in 2025, a significant jump from 14% the previous year. As the FDA tightens requirements for confirmatory trials and regulatory compliance, pharmaceutical sponsors face mounting pressure to refine their development strategies far earlier in the clinical process.

Navigating the Rebound in FDA Accelerated Approvals
Photo: Bio & News

The shifting regulatory landscape demands that sponsors move beyond initial clinical evidence to secure approval. Success now hinges on proactive planning across chemistry, manufacturing, and controls (CMC), alongside rigorous protocol design. Experts from Premier Research, including Seth DePuy and Paulla Dennis, will address these challenges during a live webinar on September 17, 2026. The session focuses on synchronizing clinical and regulatory activities to minimize development risks for therapies targeting serious medical needs. By aligning cross-functional teams early, companies can better navigate inspection readiness and the complexities of confirmatory trial requirements, ensuring their programs maintain momentum toward patient access.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!